Mouse Model of Reversible Intestinal Inflammation.
Cheong Kc Kwong Chung1, Jennifer Brasseit1, Esther Althaus-Steiner1
1Division of Experimental Pathology, Institute of Pathology, University of Bern, Bern, Switzerland.
Bio-Protocol
|August 30, 2021
Summary
Developing new therapies for inflammatory bowel disease requires understanding mucosal healing. A novel mouse model demonstrates that colitis can be reversed by depleting specific T cells, offering insights into potential treatments.
Area of Science:
- Immunology
- Gastroenterology
- Disease Modeling
Background:
- Current inflammatory bowel disease (IBD) therapies targeting immune responses show limited efficacy.
- Understanding mechanisms of mucosal healing is crucial for developing novel therapeutic strategies.
- Existing treatments for IBD often fail to achieve sustained remission or complete healing.
Purpose of the Study:
- To establish a reversible model of colitis in mice.
- To investigate mechanisms underlying mucosal healing in inflammatory bowel disease.
- To identify potential therapeutic targets for inflammatory bowel disease treatment.
Main Methods:
- Development of a colitis model in lymphopenic mice via adoptive transfer of naïve CD4+ CD45RBhi T cells.
- Induction of colitis through specific T cell transfer.
- Reversal of colitis by targeted depletion of colitogenic CD4+ T cells.
Main Results:
- A reproducible and reversible model of colitis was successfully established.
- Depletion of colitogenic CD4+ T cells effectively reversed established colitis.
- This model allows for the study of immune-mediated mucosal healing processes.
Conclusions:
- The developed mouse model provides a valuable tool for studying inflammatory bowel disease pathogenesis and healing.
- Targeting specific T cell populations offers a potential therapeutic strategy for inflammatory bowel disease.
- Further research into T cell-mediated mechanisms can lead to improved treatments for mucosal healing.
